514 G3

Drug Profile

514 G3

Alternative Names: 514G3; True human™ monoclonal antibody - XBiotech

Latest Information Update: 27 Apr 2017

Price : $50

At a glance

  • Originator XBiotech
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Staphylococcal infections

Most Recent Events

  • 03 Apr 2017 Topline adverse events data from a phase I/II trial in Staphylococcal infections released by XBiotech
  • 16 Mar 2017 XBiotech has patent protection for antibodies for preventing and treating S. aureus infections in Australia and USA
  • 16 Mar 2017 XBiotech has patents pending for antibodies for preventing and treating S. aureus infections in Australia, Brazil, Canada, Chile, China, Colombia, Europe, India, Indonesia, Israel, Japan, Malaysia, Mexico, New Zealand, Philippines, Russia, Singapore, South Korea, South Africa and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top